Literature DB >> 24287147

Insulin dependence and pancreatic enzyme replacement therapy are independent prognostic factors for long-term survival after operation for chronic pancreatitis.

Markus Winny1, Vagia Paroglou1, Hüseyin Bektas1, Alexander Kaltenborn2, Benedikt Reichert3, Lea Zachau1, Moritz Kleine1, Jürgen Klempnauer1, Harald Schrem4.   

Abstract

BACKGROUND: This retrospective, single-center, observational study on postoperative long-term results aims to define yet unknown factors for long-term outcome after operation for chronic pancreatitis. PATIENTS AND METHODS: We analyzed 147 consecutive patients operated for chronic pancreatitis from 2000 to 2011. Mean follow-up was 5.3 years (range, 1 month to 12.7 years). Complete long-term survival data were provided by the German citizen registration authorities for all patients. A quality-of-life questionnaire was sent to surviving patients after a mean follow-up of 5.7 years.
RESULTS: Surgical principles were resection (n = 86; 59%), decompression (n = 29; 20%), and hybrid procedures (n = 32; 21%). No significant influences of different surgical principles and operative procedures on survival, long-term quality of life and pain control could be detected. Overall 30-day mortality was 2.7%, 1-year survival 95.9%, and 3-year survival 90.8%. Multivariate Cox regression analysis revealed that only postoperative insulin dependence at the time of hospital discharge (P = .027; Exp(B) = 2.111; 95% confidence interval [CI], 1.089-4.090) and the absence of pancreas enzyme replacement therapy at the time of hospital discharge (P = .039; Exp(B) = 2.102; 95% CI, 1.037-4.262) were significant, independent risk factors for survival with significant hazard ratios for long-term survival. Long-term improvement in quality of life was reported by 55 of 76 long-term survivors (73%).
CONCLUSION: Pancreatic enzyme replacement should be standard treatment after surgery for chronic pancreatitis at the time of hospital discharge, even when no clinical signs of exocrine pancreatic failure exist. This study underlines the potential importance of early operative intervention in chronic pancreatitis before irreversible endocrine dysfunction is present.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24287147     DOI: 10.1016/j.surg.2013.08.012

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

Review 1.  Pancreatic Exocrine Insufficiency as a Complication of Gastrointestinal Surgery and the Impact of Pancreatic Enzyme Replacement Therapy.

Authors:  Adarsh Chaudhary; J Enrique Domínguez-Muñoz; Peter Layer; Markus M Lerch
Journal:  Dig Dis       Date:  2019-08-16       Impact factor: 2.404

Review 2.  [Duodenum-preserving pancreatic head resection in chronic pancreatitis : Limitations of the Heidelberg multicenter ChroPac study].

Authors:  H G Beger; B Mayer
Journal:  Chirurg       Date:  2018-05       Impact factor: 0.955

Review 3.  Diagnosis and Management of Exocrine Pancreatic Insufficiency.

Authors:  Chris E Forsmark
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09

4.  A 53-Year-Old Man Presenting with Pancreatic Exocrine Insufficiency 7 Years After Gastric Bypass Bariatric Surgery.

Authors:  Mohit Bhatia; Bindhiya Thomas; Sukhdev Chatu; Shamsi El-Hasani
Journal:  Am J Case Rep       Date:  2022-06-29

Review 5.  Evidence-Based Surgical Treatments for Chronic Pancreatitis.

Authors:  Jörg Kleeff; Christian Stöß; Julia Mayerle; Lynne Stecher; Matthias Maak; Peter Simon; Ulrich Nitsche; Helmut Friess
Journal:  Dtsch Arztebl Int       Date:  2016-07-25       Impact factor: 5.594

Review 6.  Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines.

Authors:  Mary E Phillips; Andrew D Hopper; John S Leeds; Keith J Roberts; Laura McGeeney; Sinead N Duggan; Rajesh Kumar
Journal:  BMJ Open Gastroenterol       Date:  2021-06

7.  Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms.

Authors:  Valentina Andreasi; Stefano Partelli; Gabriele Capurso; Francesca Muffatti; Gianpaolo Balzano; Stefano Crippa; Massimo Falconi
Journal:  J Clin Med       Date:  2019-10-03       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.